Enanta begins phase 1 trial of oral KIT inhibitor for urticaria

April 13, 2026 7:00 AM

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) announced it has dosed the first participant in a phase 1 clinical trial of EDP-978 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found